Compounds > olmesartan
Page last updated: 2024-09-04

olmesartan and Alport Syndrome

olmesartan has been researched along with Alport Syndrome in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Bae, EH; Choi, HS; Kim, CS; Kim, IJ; Kim, SW; Ma, SK; Scholey, JW; Suh, SH1
Bae, EH; Choi, HS; Kim, CS; Kim, IJ; Kim, SW; Ma, SK; Mathew, AP; Park, IK; Suh, SH; Vasukutty, A1

Other Studies

2 other study(ies) available for olmesartan and Alport Syndrome

ArticleYear
Olmesartan Attenuates Kidney Fibrosis in a Murine Model of Alport Syndrome by Suppressing Tubular Expression of TGFβ.
    International journal of molecular sciences, 2019, Aug-06, Volume: 20, Issue:15

    Topics: Angiotensin-Converting Enzyme 2; Animals; Antihypertensive Agents; Apoptosis; Biomarkers; Biopsy; Disease Models, Animal; Fibrosis; Gene Expression Regulation; Imidazoles; Kidney Tubules; Mice; Mice, Knockout; Nephritis, Hereditary; Peptidyl-Dipeptidase A; ras Proteins; Tetrazoles; Transforming Growth Factor beta; Treatment Outcome

2019
Kidney-accumulating olmesartan-loaded nanomicelles ameliorate the organ damage in a murine model of Alport syndrome.
    International journal of pharmaceutics, 2021, May-01, Volume: 600

    Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Disease Models, Animal; Imidazoles; Kidney; Mice; Nephritis, Hereditary; Tetrazoles

2021